Skip to content

US · NEOG · MEDICAL - DIAGNOSTICS & RESEARCH

Neogen Corporation (NEOG) intrinsic value and stock valuation

$10.55as of 2026-11-21 · Mkt cap 2.49B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Neogen Corporation DCF and intrinsic value

InvestorsCraft values NEOG with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from NEOG’s statements →

Neogen Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Lansing, MI 48912-1595 neogen.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$870.4M+13.2% 5y CAGRd
20122026
Net income
-$-7.9M
20122026
Free cash flow
$31.9M-10.1% 5y CAGRd
20122026
Total equity
$2.09B+20% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$870.4M$894.7M$924.2M$822.5M$527.2M
Operating income-$-21.6M$9.42M$77.4M$37.5M$58.6M
Net income-$-7.9M-$-1.09B-$-9.42M-$-22.87M$48.3M
EPSd-$-36.32K-$-5.03M-$-43.51K-$-121.08K$447.2K
Operating cash flow$83.2M$58.2M$35.3M$41M$68M
Capital expenditure-$-51.3M-$-104.59M-$-111.42M-$-65.76M-$-24.43M
Free cash flow$31.9M-$-46.35M-$-76.16M-$-24.73M$43.6M
Total assets$3.35B$3.44B$4.55B$4.55B$992.9M
Total debt$0.00$912.6M$906.2M$897.5M$0.00
Net debt-$-185.5M$783.6M$735.6M$734.3M-$-44.47M
Total equity$2.09B$2.07B$3.14B$3.13B$887.4M
Cash and short-term investments$185.5M$129M$170.9M$245.6M$381.1M
Income statement
20262025202420232022
Revenue$870.4M$894.7M$924.2M$822.5M$527.2M
Cost of revenue$461.9M$473.3M$461.6M$416.5M$284.2M
Gross profit$408.5M$421.4M$462.6M$406M$243M
Research and development expenses$18.4M$21.1M$22.5M$26M$17.1M
Selling, general and administrative expenses$411.7M$402M$382.8M$342.4M$167.4M
Other expenses$0.00-$-9.04M-$-20.03M$0.00$0.00
Operating expenses$430.1M$412M$385.2M$368.4M$184.4M
Cost and expenses$892M$885.2M$846.8M$784.9M$468.5M
Interest income$0.00$3.11M$6.36M$3.17M$1.34M
Interest expense$57.6M$71.6M$73.4M$56M$70K
Depreciation and amortization$121.9M$125.7M$121.2M$88.4M$23.7M
Ebitda$170.5M-$-937.75M$182.6M$122.3M$83.9M
Operating income-$-21.6M$9.42M$77.4M$37.5M$58.6M
Total other income/expenses, net$12.6M-$-1.14B-$-91.73M-$-59.56M$1.59M
Income before tax-$-9M-$-1.13B-$-14.3M-$-22.04M$60.2M
Income tax expense-$-1.1M-$-41.07M-$-4.88M$830K$11.9M
Net income-$-7.9M-$-1.09B-$-9.42M-$-22.87M$48.3M
Weighted average shares outstanding$217.5M$216.9M$216.5M$188.9M$107.7M
Weighted average diluted shares outstanding$217.5M$216.9M$216.5M$188.9M$108M
Balance sheet
20262025202420232022
Cash and short-term investments$185.5M$129M$170.9M$245.6M$381.1M
Net receivables$146.8M$153.4M$173M$153.3M$99.7M
Inventory$144.3M$190.9M$189.3M$133.8M$122.3M
Total current assets$604.6M$576.9M$589.2M$585.9M$626.8M
Property, plant and equipment, net$497M$356.3M$291.9M$198.8M$110.6M
Goodwill and intangible assets$2.37B$2.48B$3.65B$3.74B$250.2M
Long-term investments$0.00$0.00$230K$0.00$0.00
Total non-current assets$2.74B$2.87B$3.96B$3.97B$366.1M
Total assets$3.35B$3.44B$4.55B$4.55B$992.9M
Accounts payable$79.1M$79.6M$83.1M$76.7M$34.6M
Short-term debt$0.00$27.4M$9.99M$6.55M$0.00
Deferred revenue$3.6M$5.56M$4.63M$4.62M$5.46M
Total current liabilities$158.2M$174M$154.3M$145.5M$77.8M
Long-term debt$0.00$887.7M$898.7M$894.3M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.09B$1.2B$1.25B$1.27B$27.7M
Capital lease obligations$0.00$20.9M$17.9M$12.1M$0.00
Total liabilities$1.25B$1.37B$1.4B$1.42B$105.6M
Common stock$34.8M$34.7M$34.7M$34.6M$17.3M
Retained earnings-$-544.3M-$-536.42M$555.6M$565M$587.9M
Accumulated other comprehensive income (loss)-$-13.6M-$-28.9M-$-30.02M-$-33.25M-$-27.77M
Total equity$2.09B$2.07B$3.14B$3.13B$887.4M
Total investments$0.00$0.00$550K$82.3M$336.6M
Total debt$0.00$912.6M$906.2M$897.5M$0.00
Net debt-$-185.5M$783.6M$735.6M$734.3M-$-44.47M
Cash flow statement
20262025202420232022
Net income-$-7.9M-$-1.09B-$-9.42M-$-22.87M$48.3M
Depreciation and amortization$116.3M$125.7M$121.2M$90.5M$24.1M
Stock-based compensation$13.4M$17.3M$13.8M$10.2M$7.15M
Change in working capital$58.8M-$-5.93M-$-72.68M-$-24.2M-$-4.42M
Accounts receivable$6.8M$11.6M-$-20.1M-$-53.88M-$-7.8M
Inventory$38.2M-$-16.12M-$-55.95M$9.96M-$-21.07M
Accounts payable$19.8M-$-400K$13.8M$18.6M$20.2M
Net cash provided by operating activities$83.2M$58.2M$35.3M$41M$68M
Investments in property, plant and equipment-$-51.3M-$-104.59M-$-111.42M-$-65.76M-$-24.43M
Acquisitions, net$0.00$5.08M$110K$12.6M-$-38.74M
Net cash used for investing activities$70.5M-$-99.19M-$-29.31M$201M-$-97.23M
Common stock issued$1.6M$2.24M$2.46M$1.2M$7.93M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-99.4M-$-1.6M$1.92M-$-118.08M$6.81M
Net change in cash$56.5M-$-41.61M$7.37M$118.8M-$-31.13M
Cash at end of period$185.5M$129M$170.6M$163.2M$44.5M
Operating cash flow$83.2M$58.2M$35.3M$41M$68M
Capital expenditure-$-51.3M-$-104.59M-$-111.42M-$-65.76M-$-24.43M
Free cash flow$31.9M-$-46.35M-$-76.16M-$-24.73M$43.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Neogen Corporation

        Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.

        CEO
        Mikhael Nassif
        Employees
        2.97K
        Beta
        1.79

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Neogen Corporation (NEOG)?

        Neogen Corporation (NEOG) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NEOG undervalued?

        NEOG trades at a price of $10.55 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.